These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 21617518)

  • 1. Secondary hyperparathyroidism in HIV patients: is there any responsibility of highly active antiretroviral therapy?
    Pocaterra D; Carenzi L; Ricci E; Minisci D; Schiavini M; Meraviglia P; Bevilacqua M; Zucchi P; Bonfanti P; Rizzardini G
    AIDS; 2011 Jul; 25(11):1430-3. PubMed ID: 21617518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients.
    Seminari E; Castagna A; Soldarini A; Galli L; Fusetti G; Dorigatti F; Hasson H; Danise A; Guffanti M; Lazzarin A; Rubinacci A
    HIV Med; 2005 May; 6(3):145-50. PubMed ID: 15876279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tenofovir disoproxil fumarate and bone mineral density: a 60-month longitudinal study in a cohort of HIV-infected youths.
    Viganò A; Zuccotti GV; Puzzovio M; Pivetti V; Zamproni I; Cerini C; Fabiano V; Giacomet V; Mora S
    Antivir Ther; 2010; 15(7):1053-8. PubMed ID: 21041922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prevalence of metabolic syndrome in Danish patients with HIV infection: the effect of antiretroviral therapy.
    Hansen BR; Petersen J; Haugaard SB; Madsbad S; Obel N; Suzuki Y; Andersen O
    HIV Med; 2009 Jul; 10(6):378-87. PubMed ID: 19490178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy.
    Madeddu G; Spanu A; Solinas P; Calia GM; Lovigu C; Chessa F; Mannazzu M; Falchi A; Mura MS; Madeddu G
    Q J Nucl Med Mol Imaging; 2004 Mar; 48(1):39-48. PubMed ID: 15195003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
    J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia.
    Samaras K; Wand H; Law M; Emery S; Cooper D; Carr A
    Diabetes Care; 2007 Jan; 30(1):113-9. PubMed ID: 17192343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and factors associated with idiopathic hypercalciuria in HIV patients on combination antiretroviral therapy.
    Pocaterra D; Carenzi L; Ricci E; Minisci D; Schiavini M; Gervasoni C; Meraviglia P; Bevilacqua M; Rizzardini G; Bonfanti P
    Int J STD AIDS; 2010 Dec; 21(12):829-31. PubMed ID: 21297093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors.
    Cazanave C; Dupon M; Lavignolle-Aurillac V; Barthe N; Lawson-Ayayi S; Mehsen N; Mercié P; Morlat P; Thiébaut R; Dabis F;
    AIDS; 2008 Jan; 22(3):395-402. PubMed ID: 18195566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone disease and HIV infection.
    Rojo P; Ramos JT
    Clin Infect Dis; 2006 Jul; 43(1):111-2; author reply 113-4. PubMed ID: 16758430
    [No Abstract]   [Full Text] [Related]  

  • 11. Diagnosing hypovitaminosis D: serum measurements of calcium, phosphate, and alkaline phosphatase are unreliable, even in the presence of secondary hyperparathyroidism.
    Smith GR; Collinson PO; Kiely PD
    J Rheumatol; 2005 Apr; 32(4):684-9. PubMed ID: 15801026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum leptin and bone metabolism in HIV patients treated with highly active antiretroviral therapy.
    Madeddu G; Spanu A; Chessa F; Calia GM; Lovigu C; Mannazzu M; Falchi A; Sanna D; Mura MS; Madeddu G
    Q J Nucl Med Mol Imaging; 2009 Jun; 53(3):290-301. PubMed ID: 18596668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prevalence of secondary hyperparathyroidism in patients aged 80 and over].
    Jensen ON
    Ugeskr Laeger; 1999 Apr; 161(16):2362-4. PubMed ID: 10235041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of vitamin D deficiency and secondary hyperparathyroidism during winter in pre-menopausal Bangladeshi and Somali immigrant and ethnic Finnish women: associations with forearm bone mineral density.
    Islam MZ; Viljakainen HT; Kärkkäinen MU; Saarnio E; Laitinen K; Lamberg-Allardt C
    Br J Nutr; 2012 Jan; 107(2):277-83. PubMed ID: 21824446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vertebral fractures in AIDS patients within 6 months from highly active antiretroviral therapy initiation: two case reports.
    Gazzola L; Bini T; Pietrogrande L; Uziel L; Cicconi P; Casana M; Monforte Ad
    AIDS; 2008 May; 22(9):1094-7. PubMed ID: 18520358
    [No Abstract]   [Full Text] [Related]  

  • 16. Prevalence of bone mineral density abnormalities and related risk factors in an ambulatory HIV clinic population.
    Guillemi S; Harris M; Bondy GP; Ng F; Zhang W; Lima VD; Michaels CE; Belzberg A; Montaner JS
    J Clin Densitom; 2010; 13(4):456-61. PubMed ID: 20663695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    McComsey GA; Kendall MA; Tebas P; Swindells S; Hogg E; Alston-Smith B; Suckow C; Gopalakrishnan G; Benson C; Wohl DA
    AIDS; 2007 Nov; 21(18):2473-82. PubMed ID: 18025884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and prevalence of the metabolic syndrome in a cohort of naive HIV-infected patients: prospective analysis at 48 weeks of highly active antiretroviral therapy.
    Palacios R; Santos J; González M; Ruiz J; Márquez M
    Int J STD AIDS; 2007 Mar; 18(3):184-7. PubMed ID: 17362552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertension in an urban HIV-positive population compared with the general population: influence of combination antiretroviral therapy.
    Baekken M; Os I; Sandvik L; Oektedalen O
    J Hypertens; 2008 Nov; 26(11):2126-33. PubMed ID: 18854751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: the Manhattan HIV Brain Bank.
    Morgello S; Estanislao L; Simpson D; Geraci A; DiRocco A; Gerits P; Ryan E; Yakoushina T; Khan S; Mahboob R; Naseer M; Dorfman D; Sharp V;
    Arch Neurol; 2004 Apr; 61(4):546-51. PubMed ID: 15096404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.